Posted by Michael Wonder on 20 Jul 2023
Yikaida CAR-T cell therapy approved as a second-line therapy for new indication
18 July 2023 - The product of Fosun Kite, jointly established by Shanghai Fosun Pharmaceutical and Kite Pharma (Yikaida) for the treatment of adult large B-cell lymphoma who failed first-line immunochemotherapy or relapsed within 12 months conditionally approved by the NMPA..
This also marks the official launch of Yikaida for second-line indication.
